Ivosidenib (Tibsovo) is an IDH1 inhibitor. · Olutasidenib (Rezlidhia) is an IDH1 inhibitor that can be used to treat AML with an IDH1 mutation ...

Domein: cancer.org Bekijk meer

Drugs Approved for Acute Myeloid Leukemia (AML) · Arsenic Trioxide · Azacitidine · Cyclophosphamide · Cytarabine · Daunorubicin Hydrochloride ...

Domein: cancer.gov Bekijk meer

The most common induction regimen for AML includes cytarabine and an anthracycline drug, such as daunorubicin or idarubicin. This is called the “7+3” regimen, ...

Domein: bloodcancerunited.org Bekijk meer

Low-intensity chemo with a drug such as low-dose cytarabine (LDAC), azacitidine (Vidaza), or decitabine (Dacogen). This is often given along with a targeted ...

Domein: cancer.org Bekijk meer

by PDQATE Board · 2024 · Cited by 1 — The following types of treatment are used: Chemotherapy. Radiation therapy. Chemotherapy with stem cell transplant. Targeted therapy. Other drug ...

Domein: ncbi.nlm.nih.gov Bekijk meer

Drugs used to treat Acute Myeloid Leukemia ; Generic name: gemtuzumab systemic; Brand name: Mylotarg; Drug class: ...

Domein: drugs.com Bekijk meer

Olutasidenib is an oral IDH1 inhibitor indicated for relapsed and/or refractory acute myeloid leukemia with a confirmed IDH1 mutation (mIDH1+ R/R AML).

Domein: emedicine.medscape.com Bekijk meer

Chemotherapy for AML usually involves a combination of 2 or 3 drugs. The most common chemotherapy drug used is cytarabine (Cytosar), which may be combined with ...

Domein: cancer.ca Bekijk meer

Key AML drugs to watch in the AML pipeline include Crenolanib (Arog Pharmaceuticals), Uproleselan (GlycoMimetics), Iomab-B (Actinium ...

Domein: delveinsight.com Bekijk meer